E) All of the above are correct
All five statements about prostate cancer are accurate based on current evidence and guidelines.
Detailed Analysis of Each Statement:
A) Screening Mortality Benefit Remains Unclear
The evidence on PSA and digital rectal examination (DRE) screening reducing mortality is genuinely mixed and controversial 1. The 2013 AUA Best Practice Statement acknowledges that "it is still not clear that prostate cancer screening results in more benefit than harm" 1. The PLCO trial found no difference in prostate cancer deaths at 7-10 years, though this had methodological limitations including pre-screening contamination 1. The ERSPC trial showed some mortality reduction, but the absolute benefit was small 1. The U.S. Preventive Services Task Force concluded with moderate certainty that the net benefit of PSA-based screening in men aged 55-69 years is small, with approximately 1.3 deaths prevented per 1,000 men screened over 13 years 2.
B) Age and Patient Preference Restrictions on Screening
Screening is definitively not recommended for men over 70 years of age 2. The USPSTF gives this a Grade D recommendation, stating "the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms" due to increased false-positives, biopsy complications, and treatment harms in this age group 2.
For patient preference, the guidelines are explicit: "Clinicians should not screen men who do not express a preference for screening" 2. The 2013 AUA guidelines emphasize that screening should only occur in "well-informed men with an estimated ten year life expectancy who wish to pursue early diagnosis" 1.
C) Transrectal Ultrasound-Guided Biopsy as Diagnostic Standard
While the provided evidence doesn't explicitly state this is the "method of choice," the 2003 French guidelines indicate that "the diagnosis of prostatic adenocarcinoma is generally made using routine haematoxylin and eosin staining" on biopsy specimens 3, and multiple guidelines reference transrectal ultrasound (TRUS) findings in biopsy decisions 4. The 2012 ESMO guidelines note that "75% of detectable cancers in a screening program are nonpalpable" 4, supporting the need for TRUS-guided systematic sampling. This remains the standard approach for obtaining tissue diagnosis, though increasingly combined with MRI-targeted biopsies.
D) MRI Superior to CT for Staging
MRI is indeed more reliable than CT for local staging of prostate cancer 4. The 2012 ESMO Consensus Conference states that "MRI technology is continuously evolving, and more extensive use of MRI technology in clinical trials and practice will help to improve prostate cancer diagnosis and treatment planning" 4. MRI provides superior soft tissue contrast for assessing extracapsular extension, seminal vesicle invasion, and local tumor extent compared to CT. The 2026 EAU guidelines emphasize multiparametric MRI's role in diagnosis and staging 5.
Clinical Caveats:
- Overdiagnosis remains a major concern: Many screen-detected cancers would never become clinically significant 2, 6
- Treatment complications are substantial: Approximately 20% develop long-term urinary incontinence and 67% experience erectile dysfunction after radical prostatectomy 2
- Active surveillance is appropriate for low-risk disease and selected favorable intermediate-risk cases 7, 8
- Shared decision-making is mandatory for men aged 55-69 considering screening 2